

1 **Research Letter: Incidence of SARS-CoV-2 infection among unvaccinated US adults during the Omicron**
2 **wave**

3
4 Jennifer L. Alejo, MD¹, Teresa PY Chiang, MD, MPH¹, Jonathan Mitchell, MBBS¹, Aura T. Abedon, BS¹,
5 Alexa A. Jefferis, BS¹, William Werbel, MD¹, Allan B. Massie PhD, MHS², Martin A. Makary MD, MPH*¹,
6 Dorry L. Segev, MD PhD*²

7 *Senior authors contributed equally

8
9 (1) Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

10 (2) Department of Surgery, NYU Grossman School of Medicine, New York, NY.

11
12
13
14
15 Contact Information:

16 Dorry Segev, M.D., Ph.D.

17 Professor of Surgery

18 NYU Grossman School of Medicine

19 dorry@nyulangone.org

20

21 **Author Contributions:** Dr. Alejo had full access to all the data in the study and takes responsibility for
22 the integrity of the data and the accuracy of the data analysis.

23 *Concept and Design:* Alejo, Chiang, Mitchell, Werbel, Massie, Makary, Segev.

24 *Acquisition, analysis, interpretation of data:* All authors.

25 *Drafting of the manuscript:* All authors.

26 *Critical revision of the manuscript:* Alejo, Chiang, Mitchell, Werbel, Massie, Makary, Segev.

27 *Statistical analysis:* Alejo, Chiang, Massie, Segev.

28 *Obtained funding:* Segev.

29 *Administrative, technical, or material support:* All authors.

30 *Supervision:* Massie, Makary, Segev.

31

32 **Conflict of Interest:** DL Segev has the following financial disclosures: consulting and speaking honoraria
33 from Sanofi, Novartis, CLS Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific,
34 Astra Zeneca, and Regeneron. The remaining authors of this manuscript have no financial disclosures or
35 conflicts of interest to disclose.

36

37 **Funding/Support:** This work was supported by charitable donations from the Ben-Dov family. These
38 authors received salary support from the following grants: T32DK007713 (Dr. Alejo), The ASTS Jonathan
39 P. Fryer Resident Scientist Scholarship (Dr. Mitchell).

40

41 **Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection,
42 management, analysis, and interpretation of the data, preparation, review, or approval of the
43 manuscript, and decision to submit the manuscript for publication.

44

45 **Acknowledgement:** We acknowledge the following individuals for their assistance with this study, none
46 of whom were compensated for their contributions: Jake D. Kim, BS, and Carolyn N. Sidoti, BS, for data
47 collection and study coordination (Department of Surgery, Johns Hopkins School of Medicine); Daniel S.
48 Warren, PhD (Department of Surgery, Johns Hopkins School of Medicine), Amy Chang, MD, (Department
49 of Surgery, Johns Hopkins School of Medicine) and Macey L. Levan, JD, PhD (Departments of Acute and
50 Chronic Care, Johns Hopkins School of Nursing, and Surgery, Johns Hopkins School of Medicine) for
51 administrative and scientific support.
52

53 **Abstract**

54 As of 4/20/2022, approximately 23% of the eligible US population was unvaccinated. We studied COVID-
55 19 infections during the Omicron (B.1.1.529) wave in unvaccinated US adults, stratified by pre-Omicron
56 antibody levels. Anti-spike serologic testing was performed prior to the Omicron wave in the United
57 States (9/23/21-11/5/21) and participants were surveilled to determine incident COVID-19. Only 12% of
58 those who entered the wave with antibodies reported a test-confirmed COVID-19 infection, compared
59 to 35% of those without antibodies prior to the Omicron wave. Effectiveness of these anti-RBD
60 antibodies in this unvaccinated population was 67%. Among people with antibodies, titer did not appear
61 to be associated with risk of test-confirmed Omicron infection.

62

63

64 As of 4/20/2022, approximately 23% of the eligible US population has not received at least one SARS-
65 CoV-2-vaccine dose.[1] We recently reported that 99% of unvaccinated US adults who had a test-
66 confirmed SARS-CoV-2 infection had detectable anti-RBD antibodies up to 20 months after their positive
67 COVID-19 test.[2] However, whether these antibodies can be used as a clinical marker of protection
68 against new variants is undescribed. To better understand protective correlates, we studied COVID-19
69 infections during the Omicron (B.1.1.529) wave in unvaccinated US adults, stratified by pre-Omicron
70 antibody levels.

71

72 Methods

73 Self-described healthy adults who reported never receiving a SARS-CoV-2 vaccine were recruited for this
74 national cohort study between (9/11/2021-10/8/2021).[2] Anti-spike serologic testing was performed
75 prior to the Omicron wave (9/23/21-11/5/21), and categories of antibody titers were created based on
76 reported associations with neutralization.[3-4] Participants completed a follow-up questionnaire
77 (1/19/2022-2/7/2022) about COVID-19 test status and symptoms (since 12/1/2021): tested positive for
78 COVID-19, suspected COVID-19 but never tested positive, or no suspected infection or positive test, and
79 classified symptoms as severe, moderate, mild, or none.

80

81 Population characteristics were compared using Fisher's exact test for categorical variables and
82 Wilcoxon rank-sum test for continuous variables. All analyses were performed using Stata 17.0/SE. The
83 study was approved by the Johns Hopkins institutional review board. Participants provided informed
84 electronic consent.

85

86 Results

87 Of 843 unvaccinated adults with anti-RBD measured within two months preceding the Omicron wave,
88 566 (67%) completed the follow-up survey between 1/19/2022-2/7/2022. 20 reported interval COVID-
89 19 vaccination and were excluded. The median (interquartile range, IQR) age was 48 (37-59) years, 295
90 (54%) were women, 453 (83%) were white, 203 (37%) reported having a test-confirmed COVID-19
91 diagnosis before the Omicron wave, and 328 (60%) had anti-RBD antibodies before the Omicron wave.
92 446 (82%) reported no regular public mask use since December 1, 2021. Participants with and without
93 anti-RBD antibodies were similar with respect to age, sex, race, ethnicity, and mask use (Table).
94
95 35% of unvaccinated individuals without preexisting antibodies (anti-RBD<0.8 U/mL, n=218) reported
96 test-confirmed COVID-19; an additional 12% reported suspected/unconfirmed COVID-19 during the
97 Omicron wave. In contrast, 12% of unvaccinated individuals with preexisting antibodies (anti-RBD \geq 0.8
98 U/mL, n=328) reported test-confirmed COVID-19 and an additional 15% reported
99 suspected/unconfirmed COVID-19 during the Omicron wave. Among those with anti-RBD 0.8-1000 U/mL
100 (n=284), 12%/16% reported confirmed/suspected COVID-19, and among those with anti-RBD \geq 1000
101 U/mL (n=44), 9%/7% reported confirmed/suspected COVID-19 (Supplementary Figure).
102
103 Having antibodies was 67% effective against reporting test-confirmed COVID-19(35% vs 12% p<0.001).
104 Among those with test-confirmed COVID-19 who answered symptom questions (n=115), those with
105 antibodies reported shorter symptom duration than their antibody-negative counterparts (median[IQR]
106 3.5 [3, 5] vs. 6 [3, 8] days, p=0.013). There was a higher proportion of antibody-negative participants (vs.
107 positive) in the COVID-19-confirmed (38% vs 24%, p=0.15), and suspected/unconfirmed groups (22% vs.
108 6%, p=0.06), but neither difference was statistically significant.

109

110 Discussion

111 In this national longitudinal study of incident COVID-19 among unvaccinated adults during the Omicron
112 wave, only 12% of those who entered the wave with anti-RBD antibodies reported a test-confirmed
113 COVID-19 infection, compared to 35% of those without antibodies prior to the Omicron wave.
114 Effectiveness of these anti-RBD antibodies, presumably derived from previous infection, in this
115 unvaccinated population was 67%. Recently, reduced vaccine efficacy against Omicron has been
116 described among 4x-vaccinated Israelis, and the additional protection of a 4th dose peaked four weeks
117 post-fourth dose and waned in later weeks.[4-5] Our results add valuable information to the discussion
118 of vaccine versus infection-derived immune protection against Omicron.[6-7]

119
120 Study limitations include lack of information about direct neutralization against Omicron (though anti-
121 RBD correlation with neutralization is described), lack of viral sequencing (though follow-up occurred
122 when Omicron became the dominant strain in the US), self-reported COVID-19 test results, limited
123 availability of COVID-19 testing during the follow-up period which could lead to underreporting of
124 COVID-confirmed cases, and survivor bias.[3]

125
126 In conclusion, the presence of anti-RBD antibodies in an unvaccinated healthy adult (natural immunity)
127 was associated with 23% decreased relative risk for COVID-19 reinfection and shortened symptom
128 duration versus those without pre-existing anti-RBD antibodies during the Omicron wave. Among people
129 with antibodies, titer did not appear to be associated with risk of test-confirmed Omicron infection,
130 although our sample size for those ≥ 1000 U/mL may have been inadequate to detect such a difference
131 in that range. It is important to note that while disease severity for hospitalized Omicron patients was
132 somewhat lower for Omicron versus other variants, patients hospitalized with COVID-19 remain at
133 substantial risk of critical illness and death. [8] Our findings shed some light on COVID protection among
134 the unvaccinated-immune.

135 References

- 136 1. Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Accessed
137 2/2/2022 https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-onedose-pop-5yr
138 2. Alejo JL, Mitchell J, Chang A, et al. Prevalence and Durability of SARS-CoV-2 Antibodies Among
139 Unvaccinated US Adults by History of COVID-19. JAMA. Published online February 03, 2022.
140 doi:10.1001/jama.2022.1393
141 3. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273
142 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43-50.
143 doi:10.1126/science.abm3425
144 4. Rössler A, Riepler L, Bante D, Von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant Neutralization in
145 Serum from Vaccinated and Convalescent Persons. New England Journal of Medicine. 2022.
146 doi:10.1056/nejmc2119236.
147 5. Bar-On YM, Goldberg Y, Mandel M, et al.. Protection by a Fourth Dose of BNT162b2 against Omicron
148 in Israel. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2201570.
149 6. Luring AS, Tenforde MW, Chappell JD, et al.. Clinical severity of, and effectiveness of mRNA vaccines
150 against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States:
151 prospective observational study. BMJ. 2022:e069761. doi:10.1136/bmj-2021-069761.
152 7. Accorsi EK, Britton A, Fleming-Dutra KE, et al.. Association Between 3 Doses of mRNA COVID-19
153 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
154 JAMA. 2022. doi:10.1001/jama.2022.0470.
155 8. Regev-Yochay G, Gonen T, Gilboa M, et al.. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine
156 against Omicron. New England Journal of Medicine. 2022;386(14):1377-1380.
157 doi:10.1056/nejmc2202542.
158

159 **Table.** Participant demographics and clinical characteristics, by pre-Omicron anti-RBD level

	Total, No. (%)	Anti-RBD Antibody		P value ^a
		Negative	Positive	
No.	546	218	328	
Age, median (IQR), y	48 (37, 59)	48 (37, 62)	48 (37, 58)	0.41
Male	251 (46%)	104 (48%)	147 (45%)	0.54
Race ^b				0.34
African American/Black	7 (1%)	2 (1%)	5 (2%)	
Asian	23 (4%)	10 (5%)	13 (4%)	
White	453 (83%)	187 (86%)	266 (81%)	
Other	63 (12%)	19 (9%)	44 (13%)	
Hispanic ^b	67 (12%) (n=543)	24 (11%)	43 (13%)	0.51
Mask use since Dec 1, 2021				0.20
Yes	96 (18%)	44 (20%)	52 (16%)	
No	446 (82%)	173 (79%)	273 (83%)	
Declined to answer	4 (1%)	1 (<1%)	3 (1%)	
Anti-RBD median (IQR)	34.6 (<0.8, 228.7)	<0.8 (<0.8, <0.8)	168 (56, 499)	<0.001
Prior COVID Infection				
Prior COVID confirmed	203 (37%)	2 (1%)	201 (61%)	<0.001
Prior COVID unconfirmed	183 (34%)	71 (33%)	112 (34%)	
No prior COVID	160 (29%)	145 (67%)	15 (5%)	
Omicron-wave-confirmed	115 (21%)	77 (35%)	38 (12%)	<0.001
Symptoms: severe or moderate	38 (33%)	29 (38%)	9 (24%)	0.15
severe ^c	1 (1%)	1 (1%)	0 (0%)	
moderate ^c	37 (32%)	28 (36%)	9 (24%)	
Symptoms: mild or none	77 (67%)	48 (62%)	29 (76%)	
mild ^c	74 (64%)	45 (58%)	29 (76%)	
none ^c	3 (3%)	3 (4%)	0 (0%)	
Symptom duration median (IQR), d ^c	5 (3, 7)	6 (3, 8)	3.5 (3, 5)	0.01
Omicron-wave-suspected	76 (14%)	27 (12%)	49 (15%)	<0.001
Symptoms: severe or moderate	9 (12%)	6 (22%)	3 (6%)	0.06
severe ^d	0 (0%)	0 (0%)	0 (0%)	
moderate ^d	9 (12%)	6 (22%)	3 (6%)	
Symptoms: mild or none	67 (88%)	21 (77%)	46 (94%)	
mild ^d	64 (84%)	19 (70%)	45 (92%)	
none ^d	3 (4%)	2 (7%)	1 (2%)	
Symptom duration median (IQR), d ^d	4 (3, 5)	5 (3, 6)	4 (2, 5)	0.04
Omicron-wave-none	355 (65%)	114 (52%)	241 (73%)	<0.001

160

161 Abbreviation: RBD, receptor-binding domain.


162 ^a Fisher exact test used for categorical variables and Wilcoxon rank-sum test for continuous variables.

163 ^b Race and ethnicity were collected during recruitment to perform weighted random sampling among
 164 the 3 groups for antibody testing. Participants could select from African-American/Black, Asian, White,
 165 or other. Ethnicity was self-reported. Participants could select from Hispanic/Latino: yes/no.

166 ^c Among Omicron-wave-confirmed, N=115

167 ^d Among Omicron-wave-unconfirmed, N=76

168 **Figure. Distribution of self-reported COVID-19 infections after December 1, 2021 among unvaccinated**
169 **US Adults, stratified by pre-Omicron wave anti-RBD antibody level.**



170
171